FREQUENCY OF DEVELOPMENT OF NEUTRALIZING ANTIBODIES FOR SARS COV-2 VIRUS AFTER SINOPHARM VACCINATION - A SINGLE-CENTRE STUDY FROM ISLAMABAD, PAKISTAN

Huma Abdul Shakoor; Sundas Ali; Quratulain Akhlaq; Shazia Anwar; Zahra Rashid Khan; Samina Tufail Amanat

doi:10.46903/gjms/23.1.Special.1629

FREQUENCY OF DEVELOPMENT OF NEUTRALIZING ANTIBODIES FOR SARS COV-2 VIRUS AFTER SINOPHARM VACCINATION - A SINGLE-CENTRE STUDY FROM ISLAMABAD, PAKISTAN

Huma Abdul Shakoor, Sundas Ali, Quratulain Akhlaq, Shazia Anwar, Zahra Rashid Khan, Samina Tufail Amanat

Abstract

Background: The COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has led to high morbidity and mortality worldwide. The Sinopharm vaccine was first to be rolled out in Pakistan for mass vaccination of population at risk. The objective of this study was to determine the frequency of development of Neutralizing antibodies for SARS CoV-2 virus after Sinopharm vaccination.

Materials & Methods: It was a cross-sectional observational study conducted at the Department of Pathology of Pakistan Atomic Energy Commission General Hospital H/11 Islamabad from 2nd April 2021 to 18th May 2021. Blood samples of 114 persons of both genders who had received Sinopharm vaccination and at least three weeks had elapsed after last dose of vaccination were taken. Tests for measuring neutralizing spike antibody were performed using Roche analyser Cobas 6000. Antibodies value greater than 0.8U/ml was taken as positive antibody titre.

Results: Positive neutralizing antibody was observed in 111 (97.37%) persons while negative antibody titre was observed in 3 persons (2.63%). Of the persons who developed antibodies,74(66.67%) were males while 37 (33.33%) were females. High variability and low antibody titers were observed in age group 60 years and above and between 40 to 49 years. Gender of the subjects had no effect on antibody titre level.

Conclusion: Neutralizing antibodies to spike proteins of SARS-CoV2 after Sinopharm vaccination developed in 97.37%. High variability and low antibody titers were observed in age group 60 years and above and between 40 to 49 years.

Keywords

Antibodies; Corona; Immune system Vaccination; Virus.

Full Text:

PDF

References

World Health Organization (WHO). WHO COVID-19 Dashboard [Internet]. Geneva: World Health Organization; [updated 2021 May 20; cited 2021 May 21]. Available from: https://covid19.who.int/

National Command and Operation Centre (NCOC). National Command and Operation Centre Government of Pakistan. [Internet]. Available from: ncoc.gov.pk [Accessed 20 May 2021].

Kucharski AJ, Klepac P, Conlan AJK, Kissler SM, Tang ML, Fry H, et al. Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study. Lancet Infect Dis. 2020;20:1151-60. https://doi.org/10.1016/S1473-3099(20)30457-6

Syangtan G, Bista S, Dawadi P, Rayamajhee B, Shrestha LB, Tuladhar R, et al. Asymptomatic SARS-CoV-2 carriers: a systematic review and meta-analysis. Front Public Health. 2021;8:587374. https://doi.org/10.3389/fpubh.2020.587374

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323:1824-36. https://doi.org/10.1001/jama.2020.6019

Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8(8):e1003-e1017. https://doi.org/10.1016/S2214-109X(20)30264-3

Vellas C, Delobel P, de Souto Barreto P, Izopet J. COVID-19, virology and geroscience: a perspective. J Nutr Health Aging. 2020;24(7):685-91. https://doi.org/10.1007/s12603-020-1416-2

Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83-100. https://doi.org/10.1038/s41577-020-00479-7

World Health Organization (WHO). Draft landscape of COVID-19 candidate vaccines. 2020. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6(1):28. https://doi.org/10.1038/s41541-021-00292-w

Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237. https://doi.org/10.1038/s41392-020-00352-y

Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson WH, et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med. 2020;1(3):100040. https://doi.org/10.1016/j.xcrm.2020.100040

Wee SL, Qin A. China approves COVID-19 vaccine as it moves to inoculate millions. New York Times [Internet]. 2020 Dec 30; Available from: https://nytimes.com/2020/12/30/business/china-vaccine.html

NIKKEI Asia. UAE announces Sinopharm vaccine has 86% efficacy against COVID-19. NIKKEI Asia [Internet]. 2020. Available from: https://asia.nikkei.com/Spotlight/Coronavirus/UAE-announces-Sinopharm-vaccine-has-86-efficacy-against-COVID-19

Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32(2):e00084-18. https://doi.org/10.1128/CMR.00084-18

Bogale HA, Amhare AF, Bogale AA. Assessment of factors affecting vaccine cold chain management practice in public health institutions in East Gojam Zone of Amhara Region. BMC Public Health. 2019;19(1):1433. https://doi.org/10.1186/s12889-019-7786-x

Tregoning JS, Brown ES, Cheeseman HM, et al. Vaccines for COVID-19. Clin Exp Immunol. 2020;202(2):162-92. https://doi.org/10.1111/cei.13517

Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021;27(2):205-11. https://doi.org/10.1038/s41591-021-01230-y

Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951-60. https://doi.org/10.1001/jama.2020.15543

Scepanovic P, Alanio C, Hammer C, Hodel F, Bergstedt J, Patin E, et al. Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Med. 2018;10:1-3. https://doi.org/10.1186/s13073-018-0568-8

DOI: https://doi.org/10.46903/gjms/23.1.Special.1629